298 related articles for article (PubMed ID: 11008007)
1. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis.
Mascaux C; Paesmans M; Berghmans T; Branle F; Lafitte JJ; Lemaitre F; Meert AP; Vermylen P; Sculier JP;
Lung Cancer; 2000 Oct; 30(1):23-36. PubMed ID: 11008007
[TBL] [Abstract][Full Text] [Related]
2. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G
Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797
[TBL] [Abstract][Full Text] [Related]
4. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent.
Pujol JL; Carestia L; Daurès JP
Br J Cancer; 2000 Jul; 83(1):8-15. PubMed ID: 10883661
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer -- the use of complete response rate as the primary endpoint in phase II trials.
Dowlati A; Crosby L; Remick SC; Makkar V; Levitan N
Lung Cancer; 2001 May; 32(2):155-62. PubMed ID: 11325486
[TBL] [Abstract][Full Text] [Related]
6. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.
Souhami RL; Spiro SG; Rudd RM; Ruiz de Elvira MC; James LE; Gower NH; Lamont A; Harper PG
J Natl Cancer Inst; 1997 Apr; 89(8):577-80. PubMed ID: 9106647
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin plus etoposide versus other platin-based regimens for patients with extensive small-cell lung cancer: a systematic review and meta-analysis of randomised, controlled trials.
Jiang L; Yang KH; Guan QL; Mi DH; Wang J
Intern Med J; 2012 Dec; 42(12):1297-309. PubMed ID: 22530708
[TBL] [Abstract][Full Text] [Related]
8. Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.
Reck M; von Pawel J; Macha HN; Kaukel E; Deppermann KM; Bonnet R; Ulm K; Hessler S; Gatzemeier U
Lung Cancer; 2006 Jul; 53(1):67-75. PubMed ID: 16713013
[TBL] [Abstract][Full Text] [Related]
9. Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer.
Laurie SA; Logan D; Markman BR; Mackay JA; Evans WK;
Lung Cancer; 2004 Feb; 43(2):223-40. PubMed ID: 14739044
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Hatlevoll R; Dahle R; Boye N; Wang M; Vigander T; Vilsvik J; Skovlund E; Hannisdal E; Aamdal S;
J Clin Oncol; 2002 Dec; 20(24):4665-72. PubMed ID: 12488411
[TBL] [Abstract][Full Text] [Related]
11. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study.
Pujol JL; Daurès JP; Rivière A; Quoix E; Westeel V; Quantin X; Breton JL; Lemarié E; Poudenx M; Milleron B; Moro D; Debieuvre D; Le Chevalier T
J Natl Cancer Inst; 2001 Feb; 93(4):300-8. PubMed ID: 11181777
[TBL] [Abstract][Full Text] [Related]
12. Comparison of etoposide and cisplatin with bis-chloro-ethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer. A Southwest Oncology Group Study.
O'Bryan RM; Crowley JJ; Kim PN; Epstein RB; Neilan B; Coltman CA; Stuckey WJ; Pazdur R
Cancer; 1990 Feb; 65(4):856-60. PubMed ID: 2153435
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of etoposide area under the curve (AUC) at first chemotherapy cycle in small cell lung cancer patients: a multicenter study of the groupe Lyon-Saint-Etienne d'Oncologie Thoracique (GLOT).
Freyer G; Ligneau B; Tranchand B; Ardiet C; Souquet PJ; Court-Fortune I; Riou R; Rebattu P; Morignat E; Boissel JP; Trillet-Lenoir V; Girard P
Lung Cancer; 2001; 31(2-3):247-56. PubMed ID: 11165404
[TBL] [Abstract][Full Text] [Related]
14. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
Murray N; Livingston RB; Shepherd FA; James K; Zee B; Langleben A; Kraut M; Bearden J; Goodwin JW; Grafton C; Turrisi A; Walde D; Croft H; Osoba D; Ottaway J; Gandara D
J Clin Oncol; 1999 Aug; 17(8):2300-8. PubMed ID: 10561291
[TBL] [Abstract][Full Text] [Related]
15. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
16. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.
Klastersky J; Sculier JP; Lacroix H; Dabouis G; Bureau G; Libert P; Richez M; Ravez P; Vandermoten G; Thiriaux J
J Clin Oncol; 1990 Sep; 8(9):1556-62. PubMed ID: 2167953
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer.
Reck M; von Pawel J; Macha HN; Kaukel E; Deppermann KM; Bonnet R; Ulm K; Hessler S; Gatzemeier U
J Natl Cancer Inst; 2003 Aug; 95(15):1118-27. PubMed ID: 12902441
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial between two neoadjuvant chemotherapy protocols: CDDP + 5-FU versus CDDP + VP16 in advanced cancer of the head and neck.
Prévost A; Mérol JC; Aimé P; Moutel K; Roger-Liautaud F; Nasca S; Legros M; Coninx P
Oncol Rep; 2005 Sep; 14(3):771-6. PubMed ID: 16077990
[TBL] [Abstract][Full Text] [Related]
19. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
20. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
